Sarda Proteins Ltd (FRESITA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sarda Proteins Ltd on NSE and BSE, with an AI summary of each filing.
As Per Attachment
Financial Result · 30 Oct 2026, 11:32 pm
Fresita Proteins Reports Q2 FY27 Results and Registered Office Relocation Fresita Proteins approved standalone unaudited financial results for the quarter ended 30th Sep'26. Revenue from operations dropped to Rs 81.03 lakhs from Rs 430.38 lakhs YoY and Rs 1,299.30 lakhs QoQ. Total income stood at Rs 81.03 lakhs, with net profit after tax at Rs 13.95 lakhs versus Rs 40.46 lakhs YoY and Rs 165.97 lakhs QoQ. EPS declined to Rs 0.16. For H1 FY27, revenue reached Rs 1,380.33 lakhs with net profit of Rs 179.91 lakhs. The board also approved shifting its registered office from Rajasthan to Gujarat.
Outcome of Board Meeting_30-10-2026
Outcome · 30 Oct 2026, 11:27 pm
Sarda Proteins Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 81.0 (-81.2% YoY | -93.8% QoQ) ■ EBITDA: 19.0 (-36.7% YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 23.4 (+1643 bps YoY | Loss to Profit QoQ) ■ PAT: 14.0 (-65.5% YoY | -91.6% QoQ) ■ EPS (INR): 0.16 (-93.2% YoY | -91.4% QoQ)
Letter of Offer for the Rights issue
Rights Issue · 30 Oct 2026, 4:39 am
Board at its meeting held today, i.e. on October 26, 2026, has, inter alia considered, approved and fixed the terms of the rights issue including issue price and Record Date.
Outcome · 27 Oct 2026, 12:17 am
Fresita Proteins Approves ₹89.76 Crore Rights Issue Terms and Schedule Fresita Proteins Limited approved the terms for its rights issue of up to 74,79,917 fully paid-up equity shares (face value ₹10) at ₹120 per share (₹110 premium), raising up to ₹89.76 crore. The rights entitlement ratio is set at 5:6 (5 rights shares for every 6 shares held), with the record date fixed for 30th Oct'26. The issue opens on 12th Nov'26 and closes on 26th Nov'26. Outstanding equity shares will expand from 89,75,900 to 1,64,55,817 post-issue upon full subscription. Listing is targeted for 30th Nov'26.
Fresita Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve the Unaudited Standalone Financial ....
Intimation · 30 Oct 2026, 5:30 am
Fresita Proteins Board Meeting Scheduled for 30th Oct'26 Fresita Proteins Limited has scheduled a Board of Directors meeting on 30th Oct'26 at its Rajkot corporate office. Key agenda items include considering and approving the unaudited standalone financial results along with the limited review report for the quarter and half-year ended 30th Sep'26. Additionally, the board will evaluate and approve a proposal to shift the company's registered office from Alwar, Rajasthan, to Rajkot, Gujarat.
Fresita Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve matter in connection with ....
Intimation · 21 Oct 2026, 8:27 pm
Fresita Proteins Committee to Finalize Terms for Rs. 90 Crore Rights Issue Fresita Proteins Limited has scheduled a Rights Issue Committee meeting on 26th Oct'26 to finalize the terms of its previously approved Rights Issue of up to Rs. 90 Crore (face value ₹10 per share). The committee will determine the issue price, payment mechanism, rights entitlement ratio, record date, and issue timing. Consequently, the trading window for designated persons and insiders will remain closed from 26th Oct'26 until 48 hours following the conclusion of the meeting.
Scrutinizer''s Report
Annual General Meeting · 02 Oct 2026, 12:00 am
Fresita Proteins Secures Shareholder Approval for ₹1,000 Crore Borrowing and Investment Limits Fresita Proteins Limited announced the scrutinizer report for its AGM held on 30th Sep'26, confirming all five proposed resolutions passed with 100% approval across 7,243,317 votes cast. Key approvals include expanding the company's borrowing powers up to ₹1,000 Crore and sanctioning loans, guarantees, securities, and investments up to ₹1,000 Crore under Section 186. Shareholders also approved the adoption of financial statements, the re-appointment of director Shivam Gunvantray Zaladi, and the appointment of M/s. A H Mandaliya & Associates as statutory auditors.
ATTACHED HEREWITH PROCEEDING OF 35TH AGM
Annual General Meeting · 30 Sept 2026, 5:42 pm
Clarification of Price Movement
Others (Uncategorized) · 17 Sept 2026, 8:09 pm
Sarda Proteins Clarifies Share Price Movement Driven by Market Forces Sarda Proteins Ltd stated on 17th Sep'26 that it has no undisclosed material events, information, or impending announcements required to be reported under Regulation 30 of SEBI LODR Regulations. Responding to BSE's surveillance query regarding recent price movements, the company confirmed compliance with all disclosure requirements and noted that trading volume and price fluctuations are purely driven by market forces, investor sentiment, and sectoral dynamics beyond management's control.
AS ATTACHED
Others (Uncategorized) · 17 Sept 2026, 12:11 am
Sarda Proteins Clarifies Share Price Movement Driven Purely by Market Forces Sarda Proteins Ltd stated on 16th Sep'26 that the recent significant movement in its equity share price is purely market-driven and influenced by external market conditions. In response to a BSE surveillance inquiry regarding Regulation 30 compliance, the company confirmed that it continues to adhere strictly to corporate governance norms and has promptly disclosed all price-sensitive information and reportable events decided by its board. No undisclosed material operational or business developments are pending.
attached herewith BSE FINAL NAME CHANGE APPROVAL LETTER for our company with new SCRIP ID to be effective from 21.09.2026.
Others (Uncategorized) · 17 Sept 2026, 12:03 am
Sarda Proteins Renamed Fresita Proteins with New BSE Scrip ID Sarda Proteins Limited has officially changed its corporate name to Fresita Proteins Limited following approvals from the Ministry of Corporate Affairs on 21st Aug'26 and BSE Limited on 15th Sep'26. Consequently, effective 21st Sep'26, the company's Scrip ID and abbreviated name on BSE's BOLT Plus system (Scrip Code: 519242) will update to "FRESITA". The company is completing necessary depository formalities with NSDL and CDSL to reflect the new name and align the Scrip ID.
The Exchange has sought clarification from Sarda Proteins Ltd on September 16, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 16 Sept 2026, 11:10 pm
ATTACHED HEREWITH 35TH ANNUAL REPORT OF THE COMPANY FOR FY 2025-26
Others (Uncategorized) · 07 Sept 2026, 11:39 pm
ATTACHED HEREWITH NOTICE OF 35TH ANNUAL GENERAL MEETING
Annual General Meeting · 07 Sept 2026, 11:35 pm
As Attached.
Annual General Meeting · 07 Sept 2026, 6:16 pm
Sarda Proteins Schedules 35th AGM, Book Closure, and E-Voting Dates Sarda Proteins Limited will hold its 35th Annual General Meeting on 30th Sep'26 at 11:00 AM IST via video conferencing. The company's Register of Members and Share Transfer Books will remain closed from 24th Sep'26 to 30th Sep'26 for the AGM. The cut-off date to determine shareholder voting eligibility is set for 23rd Sep'26. The remote e-voting window will open on 26th Sep'26 at 9:00 AM IST and conclude on 29th Sep'26 at 5:00 PM IST.
Approved Agenda as per attachment.
Outcome · 07 Sept 2026, 6:04 pm
Sarda Proteins Schedules AGM and Finalizes Key Shareholder Voting Dates Sarda Proteins approved convening its Annual General Meeting on 30th Sep'26 via video conferencing. The cut-off date to determine shareholder voting eligibility is 23rd Sep'26, with the remote e-voting window active from 26th Sep'26 to 29th Sep'26. The Register of Members and Share Transfer Books will close from 24th Sep'26 to 30th Sep'26. Additionally, the board approved MUFG Intime India for e-voting and conferencing infrastructure, and appointed Practicing Company Secretary Himansu Togadiya as the scrutinizer for the voting process.
Sarda Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/09/2026 ,inter alia, to consider and approve 1. To approve and fix the day, ....
Intimation · 31 Aug 2026, 10:42 pm
RESIGNATION OF GUNVANTRAY JAYANTILAL ZALADI FROM THE POST OF DIRECTOR.
Change in Management · 05 Aug 2026, 11:49 pm
Sarda Proteins Board Approves Rights Issue of up to Rs. 100 Crore Sarda Proteins' Board, at its meeting on 05 Aug'26, approved a rights issue of equity shares for an amount not exceeding Rs. 100 crore (10,000 lakhs). The company will issue fully paid-up equity shares with a face value of Rs. 10 each to eligible shareholders. A Rights Issue Committee has been formed to oversee the process. The record date will be finalized and announced later. Concurrently, the Board noted the resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi, effective 05 Aug'26, for personal reasons.
BOARD HAS APPROVED ISSUE OF EQUITY SHARES ON RIGHT BASIS.
Others (Uncategorized) · 05 Aug 2026, 11:45 pm
Sarda Proteins Board Approves Rights Issue up to Rs. 100 Crore Sarda Proteins' Board of Directors on 05 Aug'26 approved raising capital via a rights issue of equity shares for an amount not exceeding Rs. 100 crore (10,000 lakhs). The shares will have a face value of Rs. 10 each. A Rights Issue Committee has been formed to oversee the process. The record date for shareholder eligibility will be announced later. Additionally, the board noted the resignation of non-executive director Gunvantray Jayantilal Zaladi, effective 05 Aug'26, due to personal reasons.
ATTACHED HEREWITH SCRUTINIZER REPORT FOR EGM DATED 30.07.2026
Extra Ordinary General Meeting · 01 Aug 2026, 12:10 am
Sarda Proteins EGM Resolutions Unanimously Passed by Shareholders At its EGM on 30 Jul'26, Sarda Proteins secured unanimous shareholder approval for all key resolutions. This included increasing authorized capital from ₹13 Cr to ₹100 Cr, amending the MoA main object clause, and changing the company name to "Sarda Enterprises Limited". The board also received approval for several key director appointments, including Shirish Dhirajlal Savaliya as Managing Director. All resolutions passed with 100% of votes in favour, seeing a total voter turnout of 81.69% of total share capital.
Sarda Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve attached
Intimation · 31 Jul 2026, 5:42 pm
Sarda Proteins Board to Consider Fundraising on 05-Aug-'26 Sarda Proteins Limited announced a Board of Directors meeting scheduled for 05-Aug-'26 to consider a proposal for raising funds. The fundraising may occur through various permissible modes, including the issuance of equity shares, convertible bonds/debentures, warrants, or preference shares. Potential methods specified are rights issue, private placement, preferential issue, or qualified institutions placement (QIP). The company will evaluate all options under applicable SEBI regulations and the Companies Act, 2013. This move signals a potential capital infusion for the company.
As attached
Extra Ordinary General Meeting · 30 Jul 2026, 5:29 pm
Sarda Proteins Proposes Capital Hike and Name Change to Fresita Proteins At its EGM on 30 Jul'26, Sarda Proteins proposed key resolutions for shareholder approval. These include increasing its authorised share capital from ₹13 crore to ₹100 crore to support expansion. The company also plans to change its name to "Fresita Proteins Limited" and alter its Main Object Clause to align with future business activities. Several board appointments, including a new Managing Director and Non-Executive Chairperson, were also on the agenda. Voting results will be disclosed separately.
as attached
Outcome · 23 Jul 2026, 12:20 am
Sarda Proteins Proposes Company Name Change Sarda Proteins Limited (BSE: 519242) announced on Jul 22, '26, that its Board of Directors approved a proposal to change the company's name at a meeting held on Jul 4, '26. This agenda item was omitted from the initial filing. The proposed new name is subject to approval from the Central Registration Centre (CRC), Ministry of Corporate Affairs. The change will also require alterations to the company's Memorandum and Articles of Association. The specific new name was not disclosed.
addendum attached herewith
Extra Ordinary General Meeting · 16 Jul 2026, 11:10 pm
Sarda Proteins Proposes New Auditor and Independent Director Appointments at EGM Sarda Proteins issued an addendum for its EGM on 30 Jul'26, proposing three new agenda items. The company seeks shareholder approval to appoint M/s A H Mandaliya & Associates as statutory auditors to fill a casual vacancy and for a subsequent five-year term from 01 Apr'26 to 31 Mar'31. Additionally, it proposes the appointment of Ms. Minal Surendra Jain as a Woman Independent Director for a five-year term effective 15 Jul'26. The appointments are subject to ordinary and special resolutions, respectively.
AS ATTACHED
Others (Uncategorized) · 15 Jul 2026, 11:46 pm
Sarda Proteins Reports Q1FY27 Results and Announces Key Corporate Updates Sarda Proteins posted Q1FY27 results, reporting a Profit After Tax of ₹165.97 lakhs, a significant turnaround from a loss of ₹49.34 lakhs YoY. Total revenue stood at ₹1,847.40 lakhs. Basic EPS for the quarter was ₹1.85 versus ₹(2.86) in Q1FY26. The board, meeting on 15th Jul'26, also approved the appointment of Ms. Minal Surendra Jain as an Independent Woman Director for a five-year term. Additionally, the company established a new corporate office in Gujarat and shifted its registered office within Alwar.